Cargando…
Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia
BACKGROUND: Adult T-cell leukemia (ATL) is a CD4(+) T-cell neoplasm with a poor prognosis. A previous study has shown that there is a strong correlation between the secreted matricellular protein osteopontin (OPN) level and disease severity in ATL patients. Here, we investigated the role of OPN in A...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657376/ https://www.ncbi.nlm.nih.gov/pubmed/26597716 http://dx.doi.org/10.1186/s12977-015-0225-x |
_version_ | 1782402388310622208 |
---|---|
author | Maeda, Naoyoshi Ohashi, Takashi Chagan-Yasutan, Haorile Hattori, Toshio Takahashi, Yayoi Harigae, Hideo Hasegawa, Hiroo Yamada, Yasuaki Fujii, Masahiro Maenaka, Katsumi Uede, Toshimitsu |
author_facet | Maeda, Naoyoshi Ohashi, Takashi Chagan-Yasutan, Haorile Hattori, Toshio Takahashi, Yayoi Harigae, Hideo Hasegawa, Hiroo Yamada, Yasuaki Fujii, Masahiro Maenaka, Katsumi Uede, Toshimitsu |
author_sort | Maeda, Naoyoshi |
collection | PubMed |
description | BACKGROUND: Adult T-cell leukemia (ATL) is a CD4(+) T-cell neoplasm with a poor prognosis. A previous study has shown that there is a strong correlation between the secreted matricellular protein osteopontin (OPN) level and disease severity in ATL patients. Here, we investigated the role of OPN in ATL pathogenesis and the possible application of anti-OPN monoclonal antibody (mAb) for ATL immunotherapy in NOD/Shi-scid,IL-2Rg(null) (NOG) mice. RESULTS: Subcutaneous inoculation of ATL cell lines into NOG mice increased the plasma level of OPN, which significantly correlated with metastasis of the inoculated cells and survival time. Administration of an SVVYGLR motif-recognizing anti-OPN mAb resulted in inhibition not only of tumor growth but also of tumor invasion and metastasis. The number of fibroblast activating protein-positive fibroblasts was also reduced by this mAb. We then co-inoculated mouse embryonic fibroblasts (MEFs) isolated from wild-type (WT) or OPN knockout mice together with ATL-derived TL-OmI cells into the NOG mice. The mice co-inoculated with WT MEFs displayed a significant decrease in survival relative to those injected with TL-OmI cells alone and the absence of OPN in MEFs markedly improved the survival rate of TL-OmI-inoculated mice. In addition, tumor volume and metastasis were also reduced in the absence of OPN. CONCLUSION: We showed that the xenograft NOG mice model can be a useful system for assessment of the physiological role of OPN in ATL pathogenesis. Using this xenograft model, we found that fibroblast-derived OPN was involved in tumor growth and metastasis, and that this tumor growth and metastasis was significantly suppressed by administration of the anti-OPN mAbs. Our findings will lead to a novel mAb-mediated immunotherapeutic strategy targeting against the interaction of OPN with integrins on the tumor of ATL patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12977-015-0225-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4657376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46573762015-11-25 Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia Maeda, Naoyoshi Ohashi, Takashi Chagan-Yasutan, Haorile Hattori, Toshio Takahashi, Yayoi Harigae, Hideo Hasegawa, Hiroo Yamada, Yasuaki Fujii, Masahiro Maenaka, Katsumi Uede, Toshimitsu Retrovirology Research BACKGROUND: Adult T-cell leukemia (ATL) is a CD4(+) T-cell neoplasm with a poor prognosis. A previous study has shown that there is a strong correlation between the secreted matricellular protein osteopontin (OPN) level and disease severity in ATL patients. Here, we investigated the role of OPN in ATL pathogenesis and the possible application of anti-OPN monoclonal antibody (mAb) for ATL immunotherapy in NOD/Shi-scid,IL-2Rg(null) (NOG) mice. RESULTS: Subcutaneous inoculation of ATL cell lines into NOG mice increased the plasma level of OPN, which significantly correlated with metastasis of the inoculated cells and survival time. Administration of an SVVYGLR motif-recognizing anti-OPN mAb resulted in inhibition not only of tumor growth but also of tumor invasion and metastasis. The number of fibroblast activating protein-positive fibroblasts was also reduced by this mAb. We then co-inoculated mouse embryonic fibroblasts (MEFs) isolated from wild-type (WT) or OPN knockout mice together with ATL-derived TL-OmI cells into the NOG mice. The mice co-inoculated with WT MEFs displayed a significant decrease in survival relative to those injected with TL-OmI cells alone and the absence of OPN in MEFs markedly improved the survival rate of TL-OmI-inoculated mice. In addition, tumor volume and metastasis were also reduced in the absence of OPN. CONCLUSION: We showed that the xenograft NOG mice model can be a useful system for assessment of the physiological role of OPN in ATL pathogenesis. Using this xenograft model, we found that fibroblast-derived OPN was involved in tumor growth and metastasis, and that this tumor growth and metastasis was significantly suppressed by administration of the anti-OPN mAbs. Our findings will lead to a novel mAb-mediated immunotherapeutic strategy targeting against the interaction of OPN with integrins on the tumor of ATL patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12977-015-0225-x) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-24 /pmc/articles/PMC4657376/ /pubmed/26597716 http://dx.doi.org/10.1186/s12977-015-0225-x Text en © Maeda et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Maeda, Naoyoshi Ohashi, Takashi Chagan-Yasutan, Haorile Hattori, Toshio Takahashi, Yayoi Harigae, Hideo Hasegawa, Hiroo Yamada, Yasuaki Fujii, Masahiro Maenaka, Katsumi Uede, Toshimitsu Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia |
title | Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia |
title_full | Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia |
title_fullStr | Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia |
title_full_unstemmed | Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia |
title_short | Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia |
title_sort | osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult t-cell leukemia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657376/ https://www.ncbi.nlm.nih.gov/pubmed/26597716 http://dx.doi.org/10.1186/s12977-015-0225-x |
work_keys_str_mv | AT maedanaoyoshi osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia AT ohashitakashi osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia AT chaganyasutanhaorile osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia AT hattoritoshio osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia AT takahashiyayoi osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia AT harigaehideo osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia AT hasegawahiroo osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia AT yamadayasuaki osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia AT fujiimasahiro osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia AT maenakakatsumi osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia AT uedetoshimitsu osteopontinintegrininteractionasanovelmoleculartargetforantibodymediatedimmunotherapyinadulttcellleukemia |